Log in to save to my catalogue

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase...

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_caaac1537e0d490584c256cc9feb5b61

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial

About this item

Full title

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2024-07, Vol.15 (1), p.5931-11, Article 5931

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

This open-label, non-comparative, 2:1 randomized, phase II trial (NCT03275506) in women with stage IIIC/IV high-grade serous carcinoma (HGSC) for whom upfront complete resection was unachievable assessed whether adding pembrolizumab (200 mg every 3 weeks) to standard-of-care carboplatin plus paclitaxel yielded a complete resection rate (CRR) of at...

Alternative Titles

Full title

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_caaac1537e0d490584c256cc9feb5b61

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_caaac1537e0d490584c256cc9feb5b61

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-024-46999-x

How to access this item